Dymon Asia Capital Singapore PTE. LTD. acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 16,000 shares of the company's stock, valued at approximately $1,048,000. AstraZeneca comprises about 0.2% of Dymon Asia Capital Singapore PTE. LTD.'s investment portfolio, making the stock its 23rd biggest position.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Franklin Resources Inc. increased its position in shares of AstraZeneca by 1.9% during the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock valued at $1,276,367,000 after purchasing an additional 357,894 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of AstraZeneca by 3.1% in the fourth quarter. Jennison Associates LLC now owns 15,430,963 shares of the company's stock worth $1,011,037,000 after acquiring an additional 466,416 shares during the period. Fisher Asset Management LLC grew its holdings in AstraZeneca by 4.6% during the 4th quarter. Fisher Asset Management LLC now owns 10,959,852 shares of the company's stock valued at $718,090,000 after buying an additional 479,692 shares in the last quarter. Manning & Napier Advisors LLC boosted its holdings in shares of AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company's stock valued at $245,407,000 after purchasing an additional 564,297 shares during the last quarter. Finally, Boston Partners boosted its stake in AstraZeneca by 9,985.6% during the fourth quarter. Boston Partners now owns 3,707,479 shares of the company's stock valued at $243,444,000 after buying an additional 3,670,719 shares during the last quarter. Institutional investors own 20.35% of the company's stock.
AstraZeneca Stock Up 2.6 %
NASDAQ:AZN traded up $1.72 during mid-day trading on Monday, hitting $68.01. 5,939,845 shares of the company's stock traded hands, compared to its average volume of 5,249,754. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The company has a market capitalization of $210.91 billion, a P/E ratio of 30.09, a P/E/G ratio of 1.42 and a beta of 0.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The company has a fifty day moving average of $73.35 and a 200 day moving average of $70.83.
AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.
AstraZeneca Increases Dividend
The business also recently declared a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were given a dividend of $1.03 per share. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. This represents a yield of 2%. The ex-dividend date was Friday, February 21st. AstraZeneca's dividend payout ratio (DPR) is currently 91.15%.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on AZN. Morgan Stanley started coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating for the company. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $89.75.
Get Our Latest Stock Analysis on AstraZeneca
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
